Download Free Oncoimmunology Book in PDF and EPUB Free Download. You can read online Oncoimmunology and write the review.

Volume 1 of Dr. Jesse Stoff's "Integrative Onco-Immunology" -the first text of its kind detailing the groundbreaking approach for treating cancer patients through the support of the immune system. This book series pays homage to the complexity of the human body and recognizes that no two cancer patients are alike, either in the underlying causes of the disease or in therapeutic treatment. THE STOFF PROTOCOL of treatment brilliantly gets to the root of the problem! Once the underlying cause of the disease has been identified and reversed, the patient stands a good chance of going into remission or at least finding dramatic improvement in quality and quantity of life... Dr. Stoff leads the way toward a new healing system that's more clinically effective, more humane, and more cost effective.
Tumor Immunology and Immunotherapy - Integrated Methods Part B, Volume 636 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Chapters in this update include Quantification methods of Transforming Growth Factor beta (TGF?ß) activity in the setting of cancer immunotherapy, Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses, Tracking and interrogating tissue-resident and recruited microglia in brain tumors, Metabolomics and lipidomics of the tumor microenvironment, Monitoring abscopal responses to radiation in mice, and much more. - Provides an array of authors who are authorities in the field - Presents comprehensiveness coverage of the topics - Includes a broad level of detail and in-depth coverage
Ionizing Radiation and the Immune Response, Part B, Volume 378 reviews the latest knowledge on the immune response induced by ionizing radiations. Specific chapters in this new release include NK functions in radio-induced immune response, TRT and immune response, Radio-induced immune response and lipid metabolism, Effect of protons and heavy ions on immune response, Effect of flash therapy and mini beam on immune response, Radio-induced lymphopenia, CT to potentiate radio-induced immune response, Impact of RT on healthy tissues (inflammation), Radio-induced macrophagic response, To use nanoparticles and ionizing radiations to modulate immune response: opinion of the chemist, biologist and clinician, and much more. Other sections cover the Role of Dendritic cells in radiation-induced immune response, the Relationship between the tumor microenvironment and the efficacy of the radiotherapy/immunotherapy combination, and Biomarkers of radiation induced response to optimize radio-immunotherapy combination. - Covers the latest insights about the biological parameters modulating radio-induced immune response - Provides an accurate review by selected experts of the impact on the immune response of radio-enhancer nanoparticles or chemotherapy targeting immunosuppressive immune cells - Presents valuable information to clinicians to optimize radiotherapy and immunotherapy combinations
Myeloid Derived Suppressor Cells (MDSCs) are a heterogeneous population of immature myeloid cells that can suppress the function of multiple immune cells and in particular, T cells, through various mechanisms. MDSCs can be divided into two major subtypes based on their cell surface phenotype and morphology: polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC). Additional subtypes have been proposed, such as the early MDSC (e-MDSC) that lack both macrophage and granulocyte markers. There is still considerable ambiguity about the phenotype of these cells that corresponds to their immunosuppressive function and there are on-going challenges on how to identify, purify and/or potentially generate and expand these cells in vitro. MDSCs were first discovered in cancer patients where they have been most extensively studied as components of the immunosuppressive tumor microenvironment. In the last several years, however, the importance of their immunomodulatory role in many other disease and clinical settings has emerged. Acknowledgments We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS). We hereby state publicly that the IUIS has had no editorial input in articles included in this Research Topic, thus ensuring that all aspects of this Research Topic are evaluated objectively, unbiased by any specific policy or opinion of the IUIS.
Although cancer vaccines have yielded promising results both in vitro and in animal models, their translation into clinical application has not been very successful so far. Through the success of immune checkpoint inhibitors, the tumor immunotherapy field revived and led to important new insights. A better understanding of the functional capacity of different dendritic cell (DC) subsets and the immunogenicity of tumor antigens, more particularly of neoantigens, have important implications for the improvement of cancer vaccines. These insights can guide the development of novel strategies, to enhance the clinical utility of cancer vaccines. The aim of this Research Topic is therefore to provide a comprehensive overview of current issues regarding cancer vaccine development with an emphasis on novel approaches toward enhancing their efficacy.
Immunotherapy is a clinically proven concept to prevent and treat diverse diseases. Therapeutic monoclonal antibodies (mAb) have transformed cancer patient survival and the quality of life for patients with inflammatory and autoimmune diseases. Vaccination with attenuated viruses or microbial virulence factors is a validated strategy to control infectious disease and has eradicated the global pandemic Smallpox infection. Recently, the concept of encoding transgenes, such as the receptor-binding COVID-19 spike protein, cytokines, antibodies, or immunogenic tumor antigens into non-viral or viral vectors has been validated as a powerful means to achieve vaccination for protection against pandemic infections, and cancer immunotherapy respectively. For certain immunotherapeutic targets and mechanisms, vector-based targeting offers distinct advantages over the traditional protein format. For example, in cancer immunotherapy vectorization may enable local delivery, production, and tumor-enriched exposure of powerful immune-modulatory antibodies, for example anti-CTLA-4 or anti-CD28 that are too toxic to allow full therapeutic dosing upon systemic administration.